Citations

Showing 10 of 108104 citations.

Impact of the Society for Research on Nicotine and Tobacco Health Disparities Network’s Scholarship on Professional Development of Its Recipients
Hickman, Norval, Choi, Kelvin , Robinson, Cendrine , Fagan, Pebbles , Okuyemi, Kolawole S. , Nahvi, Shadi , Patten, Christi A. , Davis, Danielle R.

Mayo Clinic

Nicotine & Tobacco Research | November 21, 2018 | Volume: 22 | Issue: 1 | Pages: 141-143

10.1093/ntr/nty253 | PMID 30476316 Get It

Abstract Introduction Diversifying the workforce is an important strategy to reducing health disparities. Since 2007, the Society for Research on Nicotine and Tobacco (SRNT) Health Disparities Network has funded a travel scholarship to promote inclusion, professional development, and diversity among investigators interested in tobacco-related health disparities research. This study examined indicators of productivity among former scholarship recipients. Methods: Scholarship recipients between 2007 and 2014 were invited to complete a survey online. The survey assessed demographic characteristics, academic productivity, and perceived professional benefit resulting from the scholarship. Results: Of the 117 scholarships recipients, 89 (77%) responded. Respondents were 67% female and had a mean age of 37.8 years. Twenty eight percent were African American, 25% Asian American, and 17% Latino. Most respondents worked in academia (80%) and nearly three-quarters (74%) reported publishing manuscripts on tobacco-related disparities, with a mean of 3.8 (SD 4.4) disparities-related publications since receiving the scholarship. Respondents’ work focused on a wide range of health disparities topics and nearly all respondents reported that the scholarship removed barriers to attending the meeting and reported professional benefit from receiving the travel scholarship. Following receipt of the SRNT travel scholarship, a diverse group of scientists demonstrated scholarly productivity, professional development, and advancement of health disparities research. Similar efforts are encouraged in other professional societies. Implications This study examines the productivity of early career recipients of the SRNT Health Disparities Scholarship. Results suggest that the investment in annual travel scholarships by a professional organization is an important support system for emerging scientists from diverse backgrounds. This investment may help to advance the science of health disparities and engage researchers in an area where there are critical gaps in the research workforce.
Appropriate Timing for Follow-Up CT Imaging for Stable Lung CT Screening Reporting and Data System Category 3 Lesions Identified at Baseline Low-Dose CT
Panse, Prasad M., Cummings, Kristopher W. , Gotway, Michael B.

Mayo Clinic

American Journal of Roentgenology | November 21, 2018 | Volume: 211 | Issue: 6 | Pages: W301-W301

10.2214/ajr.18.20216 | PMID 30462542 Get It

Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis
Zhu, Changyu , Kim, KyeongJin , Bartolomé, Alberto , Salomao, Marcela , Dongiovanni, Paola , Meroni, Marica , Graham, Mark J., Yates, Katherine P. , Diehl, Anna Mae , Schwabe, Robert F. , Tabas, Ira , Valenti, Luca , Lavine, Joel E. , Bartolome, Alberto , Salomao, Marcela , Dongiovanni, Paola , Yates, Katherine P , Diehl, Anna Mae , Schwabe, Robert F , Tabas, Ira , Valenti, Luca , Pajvani, Utpal B. , Wang, Xiaobo

Mayo Clinic

Science Translational Medicine | November 21, 2018 | Volume: 10 | Issue: 468 | Pages: No page available

10.1126/scitranslmed.aat0344 | PMID 30463916 Get It

Aberrant hepatocyte Notch activation is required for development of NASH-associated fibrosis, and Notch inhibition ameliorates obesity-induced liver disease.
Increased Rates of Meal Absorption Do Not Explain Elevated 1-Hour Glucose in Subjects With Normal Glucose Tolerance
Adams, J.D. , Treiber, Gerlies , LAURENTI, MARCELLO C. , Man, Chiara Dalla , Rizza, Robert A., Vella, Adrian , Hurtado, Maria Daniela , Vella, Adrian , Dalla Man, Chiara , Hurtado, Maria D. , Cobelli, Claudio

Mayo Clinic

Journal of the Endocrine Society | November 21, 2018 | Volume: 3 | Issue: 1 | Pages: 135-145

10.1210/js.2018-00222 | PMID 30591957 Get It

Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia
Vassilaki, Maria , Aakre, Jeremiah A. , Kremers, Walter K. , Mielke, Michelle M. , Geda, Yonas E. , Coloma, Preciosa M. , Schäuble, Barbara, Vemuri, Prashanthi , Lowe, Val J. , Jack, Clifford R. , Petersen, Ronald C. , Roberts, Rosebud O., Jack, Clifford R , Mielke, Michelle M , Vemuri, Prashanthi , Geda, Yonas E , Kremers, Walter K , Machulda, Mary M. , Knopman, David S.

Mayo Clinic

Journal of the American Geriatrics Society | November 21, 2018 | Volume: 66 | Issue: 12 | Pages: 2274-2281

10.1111/jgs.15577 | PMID 30462843 Get It

Objectives To examine the cross‐sectional association between functional performance and Alzheimer's disease (AD) neuroimaging biomarkers in individuals without dementia (cognitively unimpaired (CU), and those with mild cognitive impairment (MCI)). Design Cross‐sectional. Setting Olmsted County, Minnesota. Participants Population‐based Mayo Clinic Study of Aging (MCSA) participants (aged ≥ 50, mean age 71.3 ± 10.2; 53.4% male; 28.3% apolipoprotein (APO)E ε4 allele carriers, 1,578 CU, 204 MCI) who underwent 11 C‐Pittsburgh compound B ( 11 C‐PiB) positron emission tomography (PET) (N=1,782). Measurements We defined an abnormal (high) 11 C‐PiB‐PET retention ratio as a standardized uptake value ratio greater than 1.42 (high amyloid; A+), abnormal (reduced) AD signature cortical thickness (neurodegeneration; N+) as less than 2.67 mm (MRI measurement), and biomarker groups according to the combination of abnormality (or not) for amyloid accumulation (A+/A–) and neurodegeneration (N+/N–). Functional performance was assessed using the Clinical Dementia Rating (CDR) Sum of Boxes (SOB) for functional domains and the Functional Activities Questionnaire (FAQ). Results Participants with a CDR‐SOB (functional) score greater than 0 were almost 4 times as likely to have N + (odds ratio (OR)=3.92, 95% confidence interval (CI)=1.77–8.67, adjusting for age, sex, education, global cognitive z‐score, and APOE ε4 allele status; p<.001) and those with a FAQ score greater than 0 were 1.5 times as likely to have A + (OR=1.48, 95% CI=1.04–2.11, p=.03). Higher FAQ scores were associated with greater odds of A+N + and A–N + in CU participants. Conclusion The findings of this cross‐sectional study supplement limited available information that supports an association between functional performance and AD neuroimaging biomarkers very early in the dementia pathophysiology. The associations should be validated in longitudinal studies. J Am Geriatr Soc 66:2274–2281, 2018 .
GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score
Yang, Ju Dong , Addissie, Benyam D., Mara, Kristin C. , Harmsen, William S. , Dai, Jianliang , Zhang, Ning , Wongjarupong, Nicha , Ali, Hawa M. , Ali, Hamdi A. , Hassan, Fatima, Lavu, Sravanthi , Cvinar, Jessica, Giama, Nasra H., Moser, Catherine D., Miyabe, Katsuyuki , Allotey, Loretta K., Theobald, Jannick , Ward, Melissa M., Nguyen, Mindie H. , Befeler, Alex S. , Reddy, K. Rajender , Schwartz, Myron , Harnois, Denise M. , Srivastava, Sudhir , Rinaudo, Jo Ann, Feng, Ziding , Marrero, Jorge A. , Roberts, Lewis R. , Hassan, Fatima A, Cvinar, Jessica L, Theobald, J Paul, Roberts, Lewis R , Miyabe, Katsuyuki , Mara, Kristin C , Yang, Ju Dong , Algeciras‐Schimnich, Alicia , Theobald, J. Paul, Yamada, Hiroyuki , Gores, Gregory J.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 21, 2018 | Volume: 28 | Issue: 3 | Pages: 531-538

10.1158/1055-9965.epi-18-0281 | PMID 30464023 Get It

Abstract Background: The GALAD score is a serum biomarker–based model that predicts the probability of having hepatocellular carcinoma (HCC) in patients with chronic liver disease. We aimed to assess the performance of the GALAD score in comparison with liver ultrasound for detection of HCC. Methods: A single-center cohort of 111 HCC patients and 180 controls with cirrhosis or chronic hepatitis B and a multicenter cohort of 233 early HCC and 412 cirrhosis patients from the Early Detection Research Network (EDRN) phase II HCC Study were analyzed. Results: The area under the ROC curve (AUC) of the GALAD score for HCC detection was 0.95 [95% confidence interval (CI), 0.93–97], which was higher than the AUC of ultrasound (0.82, P &lt;0.01). At a cutoff of −0.76, the GALAD score had a sensitivity of 91% and a specificity of 85% for HCC detection. The AUC of the GALAD score for early-stage HCC detection remained high at 0.92 (95% CI, 0.88–0.96; cutoff −1.18, sensitivity 92%, specificity 79%). The AUC of the GALAD score for HCC detection was 0.88 (95% CI, 0.85–0.91) in the EDRN cohort. The combination of GALAD and ultrasound (GALADUS score) further improved the performance of the GALAD score in the single-center cohort, achieving an AUC of 0.98 (95% CI, 0.96–0.99; cutoff −0.18, sensitivity 95%, specificity 91%). Conclusions: The performance of the GALAD score was superior to ultrasound for HCC detection. The GALADUS score further enhanced the performance of the GALAD score. Impact: The GALAD score was validated in the United States.
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma
Aljama, Mohammed A. , Lakshman, Arjun , Jevremović, Dragan , Lacy, Martha Q. , Dingli, David , Muchtar, Eli , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Warsame, Rahma , Kourelis, Taxiarchis , Hwa, Yi L. , Kapoor, Prashant , Kyle, Robert A. , Kumar, Shaji , Lakshman, Arjun , Muchtar, E , Jevremovic, Dragan , Dingli, David , Sidiqi, M Hasib , Dispenzieri, Angela , Gertz, Morie A. , Buadi, Francis K. , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | November 21, 2018 | Volume: 2 | Issue: 22 | Pages: 3149-3154

10.1182/bloodadvances.2018024794 | PMID 30463914 Get It

Abstract The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26%) patients had an elevated PCPI (&gt;0.5). An elevated PCPI predicted an inferior time to progression (median, 3.0 vs 7.1 years for those with a low PCPI; P = .0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI (49% vs. 20%; P &lt; .0001). PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow-up and consideration of early intervention trials.
Prediction of GluN2B-CT1290-1310/DAPK1 Interaction by Protein–Peptide Docking and Molecular Dynamics Simulation
Tu, Gao, Fu, Tingting , Yang, Fengyuan , Yao, Lixia , Xue, Weiwei , Zhu, Feng , Fu, Tommy

Mayo Clinic

Molecules | November 21, 2018 | Volume: 23 | Issue: 11 | Pages: 3018

10.3390/molecules23113018 | PMID 30463177 Get It

The interaction of death-associated protein kinase 1 (DAPK1) with the 2B subunit (GluN2B) C-terminus of N-methyl-D-aspartate receptor (NMDAR) plays a critical role in the pathophysiology of depression and is considered a potential target for the structure-based discovery of new antidepressants. However, the 3D structures of C-terminus residues 1290–1310 of GluN2B (GluN2B-CT1290-1310) remain elusive and the interaction between GluN2B-CT1290-1310 and DAPK1 is unknown. In this study, the mechanism of interaction between DAPK1 and GluN2B-CT1290-1310 was predicted by computational simulation methods including protein–peptide docking and molecular dynamics (MD) simulation. Based on the equilibrated MD trajectory, the total binding free energy between GluN2B-CT1290-1310 and DAPK1 was computed by the mechanics generalized born surface area (MM/GBSA) approach. The simulation results showed that hydrophobic, van der Waals, and electrostatic interactions are responsible for the binding of GluN2B-CT1290–1310/DAPK1. Moreover, through per-residue free energy decomposition and in silico alanine scanning analysis, hotspot residues between GluN2B-CT1290-1310 and DAPK1 interface were identified. In conclusion, this work predicted the binding mode and quantitatively characterized the protein–peptide interface, which will aid in the discovery of novel drugs targeting the GluN2B-CT1290-1310 and DAPK1 interface.
Predictors of Exercise Capacity in Patients with Hypertrophic Obstructive Cardiomyopathy
Smith, Joshua R. , Medina‐Inojosa, José R. , Layrisse, Veronica, Ommen, Steve R. , Olson, Thomas P. , Smith, Joshua R , Medina-Inojosa, José R

Mayo Clinic

Journal of Clinical Medicine | November 21, 2018 | Volume: 7 | Issue: 11 | Pages: 447

10.3390/jcm7110447 | PMID 30453671 Get It

Hypertrophic obstructive cardiomyopathy (HOCM) patients exhibit compromised peak exercise capacity (VO2peak). Importantly, severely reduced VO2peak is directly related to increased morbidity and mortality in these patients. Therefore, we sought to determine clinical predictors of VO2peak in HOCM patients. HOCM patients who performed symptom-limited cardiopulmonary exercise testing between 1995 and 2016 were included for analysis. Peak VO2 was reported as absolute peak VO2, indexed to body weight and analyzed as quartiles, with quartile 1 representing the lowest VO2peak. Step-wise regression models using demographic features and clinical and physiologic characteristics were created to determine predictors of HOCM patients with the lowest VO2peak. We included 1177 HOCM patients (age: 53 ± 14 years; BMI: 24 ± 12 kg/m2) with a VO2peak of 18.0 ± 5.6 mL/kg/min. Significant univariate predictors of the lowest VO2peak included age, female sex, New York Health Association (NYHA) class, BMI, left atrial volume index, E/e’, E/A, hemoglobin, N-terminal pro b-type natriuretic peptide (NT-proBNP), and a history of diabetes, hypertension, stroke, atrial fibrillation, or coronary artery disease. Independent predictors of the lowest VO2peak included age (OR, CI: 1.03, 1.02–1.06; p < 0.0001), women (4.66, 2.94–7.47; p = 0.001), a history of diabetes (2.05, 1.17–3.60; p = 0.01), BMI (0.94, 0.92–0.96; p < 0.0001), left atrial volume index (1.07, 1.05–1.21; p = 0.04), E/e’ (1.05, 1.01–1.08; p = 0.004), hemoglobin (0.76, 0.65–0.88; p = 0.0004), and NT-proBNP (1.72, 1.42–2.11; p < 0.0001). These findings demonstrate that demographic factors (i.e., age and sex), comorbidities (e.g., diabetes and obesity), echocardiography indices, and biomarkers (e.g., hemoglobin and NT-proBNP) are predictive of severely compromised VO2peak in HOCM patients.
Effect of plasma exchange on antifactor Xa activity of enoxaparin and serum levetiracetam levels
Peters, Bradley J. , Hofer, Mikaela , Daniels, Craig E, Daniels, Craig , Winters, Jeffrey L.

Mayo Clinic

American Journal of Health-System Pharmacy | November 21, 2018 | Volume: 75 | Issue: 23 | Pages: 1883-1888

10.2146/ajhp170885 | PMID 30463865 Get It